Levels of Atherosclerotic Index of Plasma and Triglyceride Glucose Index in Patients with Psoriatic Arthritis and Carotid Plaque - ACR Meeting Abstracts

Abstract Number: 0494

Levels of Atherosclerotic Index of Plasma and Triglyceride Glucose Index in Patients with Psoriatic Arthritis and Carotid Plaque

Dionicio A. Galarza-Delgado¹, Iris Colunga¹, José Ramón Azpiri-López¹, Valeria Gonzalez-Gonzalez², Rosa Arvizu-Rivera³, Victor Beltran⁴, Angel Arias Peralta⁵ and Jesus Alberto Cardenas-De la Garza⁶, ¹Hospital Universitario UANL, Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ⁴Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁵Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, Psoriatic arthritis, Spondyloarthropathies, Subclinical Cardiovascular Disease

Session Information

Date: Sunday, November 12, 2023

Title: (0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Triglyceride Glucose Index (TyG) is a surrogate marker positively correlated with atherosclerotic burden in patients with psoriatic arthritis (PsA). Atherosclerotic index of plasma (AIP) levels have not been evaluated in patients with subclinical atherosclerosis and PsA. The objective was to compare levels of AIP and TGI between PsA-patients with and without carotid plaque (CP).

Methods: Cross-sectional study that included PsA-patients aged 40 to 75 years old who fulfilled the 2006 Classification Criteria for PsA. Patients with previous cardiovascular disease were excluded. Carotid ultrasound was performed on all study participants. The presence of carotid plaque (CP) was defined as diffuse carotid intima-media thickness (cIMT) ≥1.2 mm or focal thickness ≥0.5 mm. Subclinical atherosclerosis was defined as the presence of CP or an increased cIMT (≥0.8mm). Cardiovascular disease risk was evaluated using the algorithm: FRS-Lipids. AIP was defined by Log (TG/HDL-C) mg/dL. TGI was defined by Log (Fasting triglyceride (mg/dl) x fasting glucose (mg/dl)/2. The distribution between groups was assessed with the Kolmogorov-Smirnov test. Comparisons with Chi-square or Fisher’s exact test and Student’s t-test or Mann Whitney’s U-test, accordingly. The correlation between the AIP, TGI, cIMT, and FRS-Lipids was assessed by Spearman’s correlation coefficient. A value of p≤0.05 was considered statistically significant.

Results: A total of 88 patients with PsA were included, mostly women (n=46, 52.3%), the mean age was 53 ± 11.3, median disease duration of PsA was 5.0 (3.0-10.7) years. Median AIP was 0.44 (0.31-0.66) and TGI 3.8 (3.6-4.0) of all patients included. The most prevalent cardiovascular risk factor was dyslipidemia (n= 36, 41.4%). Patients with carotid plaque and PsA presented higher TyG compared to the group without carotid plaque (p=0.010). (Table 1).

Conclusion: AIP is not elevated in patients with PsA and subclinical atherosclerosis. However, TyG levels are increased in PsA-patients and CP. Prospective studies are needed to evaluate the performance of these surrogate markers to predict CV events in these patients.

Table 1. Demographic characteristics.

Table 2. Association between cardiovascular algorithm, cIMT and index.

Figure 1. Scatterplots of the association between cardiovascular algorithm, cIMT and index.

Disclosures: D. Galarza-Delgado: None; I. Colunga: None; J. Azpiri-López: None; V. Gonzalez-Gonzalez: None; R. Arvizu-Rivera: None; V. Beltran: None; A. Arias Peralta: None; J. Cardenas-De la Garza: None.

To cite this abstract in AMA style:

Galarza-Delgado D, Colunga I, Azpiri-López J, Gonzalez-Gonzalez V, Arvizu-Rivera R, Beltran V, Arias Peralta A, Cardenas-De la Garza J. Levels of Atherosclerotic Index of Plasma and Triglyceride Glucose Index in Patients with Psoriatic Arthritis and Carotid Plaque [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/levels-of-atherosclerotic-index-of-plasma-and-triglyceride-glucose-index-in-patients-with-psoriatic-arthritis-and-carotid-plaque/. Accessed .

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/levels-of-atherosclerotic-index-of-plasma-and-triglyceride-glucose-index-in-patients-with-psoriatic-arthritis-and-carotid-plaque/

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].